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RESEARCH ARTICLE Open Access
Ventriculoperitoneal shunt insertion in
human immunodeficiency virus infected
adults: a systematic review and meta-
analysis
James J. M. Loan1,2,3*, Michael T. C. Poon1,2, Steven Tominey2, Ncedile Mankahla3, Graeme Meintjes4 and
A. Graham Fieggen3
Abstract
Background: Hydrocephalus is a common, life threatening complication of human immunodeficiency virus (HIV)-
related central nervous system opportunistic infection which can be treated by insertion of a ventriculoperitoneal
shunt (VPS). In HIV-infected patients there is concern that VPS might be associated with unacceptably high
mortality. To identify prognostic indicators, we aimed to compare survival and clinical outcome following VPS
placement between all studied causes of hydrocephalus in HIV infected patients.
Methods: The following electronic databases were searched: The Cochrane Central Register of Controlled Trials,
MEDLINE (PubMed), EMBASE, CINAHL Plus, LILACS, Research Registry, the metaRegister of Controlled Trials,
ClinicalTrials.gov, African Journals Online, and the OpenGrey database. We included observational studies of HIV-
infected patients treated with VPS which reported of survival or clinical outcome. Data was extracted using
standardised proformas. Risk of bias was assessed using validated domain-based tools.
Results: Seven Hunderd twenty-three unique study records were screened. Nine observational studies were
included. Three included a total of 75 patients with tuberculous meningitis (TBM) and six included a total of 49
patients with cryptococcal meningitis (CM). All of the CM and two of the TBM studies were of weak quality. One of
the TBM studies was of moderate quality. One-month mortality ranged from 62.5–100% for CM and 33.3–61.9% for
TBM. These pooled data were of low to very-low quality and was inadequate to support meta-analysis between
aetiologies. Pooling of results from two studies with a total of 77 participants indicated that HIV-infected patients
with TBM had higher risk of one-month mortality compared with HIV non-infected controls (odds ratio 3.03; 95%
confidence-interval 1.13–8.12; p = 0.03).
Conclusions: The evidence base is currently inadequate to inform prognostication in VPS insertion in HIV-infected
patients. A population-based prospective cohort study is required to address this, in the first instance.
Keywords: Systematic review, Meta-analysis, Ventriculoperitoneal shunt, Cerebrospinal fluid, Hydrocephalus, Human
immunodeficiency virus, Acquired immunodeficiency syndrome
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Background
Description of the condition
Human immunodeficiency virus (HIV) is the causative
pathogen for the acquired immunodeficiency syndrome
(AIDS). Without treatment, AIDS will usually occur
within 10 years of HIV seroconversion [1–3]. AIDS may
predispose to raised cerebrospinal fluid (CSF) pressures
and hydrocephalus by various aetiologies. These include
tuberculous meningitis (TBM), cryptococcal meningitis
(CM), primary central nervous system (CNS) lymphoma,
coccoidal meningitis and immune reconstitution inflam-
matory syndrome (IRIS) [4–8].
In the absence of permanent CSF diversion therapy,
the identification and treatment underlying causative
factors will often result in normalisation of CSF hydro-
dynamics. Sometimes however, a state of chronically
raised CSF pressure develops [9]. Age-related cerebral
tissue loss as well as HIV associated neurocognitive dis-
order are associated with enlargement of CSF spaces due
to generalised brain atrophy and may result in the radio-
logical appearance of hydrocephalus, but are associated
with normal CSF pressure and flow, so called “hydro-
cephalus ex vacuo” [10, 11]. This is not an indication for
surgical treatment and, consequently, is not discussed in
this study [10].
Meningeal infections including TBM, cryptococcal
meningitis and bacterial meningitis, may impair CSF re-
sorption at arachnoid granulations, resulting in commu-
nicating hydrocephalus [9, 12, 13]. Additionally, in TBM,
where thick basal exudate may occlude ventricular out-
flow pathways, non-communicating hydrocephalus can
develop [14]. Without appropriate antimicrobial treat-
ment, TBM with associated hydrocephalus is almost uni-
versally fatal, although this is believed to be principally a
consequence of basal cerebral vasculitis and infarction,
rather than hydrocephalus [15, 16]. Even with optimal
medical management, death occurs in 30% of HIV non-
infected patients with TBM, and many of those in whom
antimicrobial management is successful suffer from
chronic hydrocephalus [17, 18]. In the context of HIV
infection, medically managed TBM has been reported to
be associated with over 4 times higher mortality than
HIV non-infected patients [18–20]. This excess mortality
might be a consequence of synergistic virulence mecha-
nisms of HIV and Mycobacterium tuberculosis, depletion
of physiological reserve consequent to chronic HIV in-
fection and demographic differences between HIV-
infected and non-HIV infected populations [21–26].
Other HIV-associated meningeal infections, such as
CM more typically result in communicating hydroceph-
alus, which usually resolves with successful antimicrobial
treatment and intermittent therapeutic lumbar puncture
to treat initially raised CSF pressures [9, 13, 27]. How-
ever, insertion of a temporary CSF drainage system
might be required to acutely control extremely high ini-
tial CSF pressures and, where raised pressure persists, a
permanent CSF shunt may be required [28].
Description of the intervention
A ventriculoperitoneal shunt (VPS) consists of a surgi-
cally implanted catheter running from the cerebral ven-
tricles into the peritoneal cavity. This permits drainage
of excess CSF according to prespecified parameters de-
termined by a pressure or flow-regulated valve [29]. To
reduce VPS associated infection, the catheter may be im-
pregnated with the antibiotics rifampicin and clindamy-
cin [30]. Catheter impregnation with silver has also been
trialled [30].
Complications of VPS insertion include infection,
catheter occlusion, migration or fracture, and over- or
under-drainage [31]. In a United States adult cohort, ap-
proximately 20% of patients suffered a complication in
the first year post-insertion, whereas in a Kenyan, mostly
paediatric, cohort this rate was recorded at 35% [32, 33].
This latter cohort possibly underestimates complication
rates in this high-HIV prevalence, lower-middle income
country because of high risk of attrition bias [33–35].
Alternatives to VPS include ventriculoatrial and ventri-
culopleural shunting. Where acute, temporary cranial
CSF diversion is required an external ventricular drain
(EVD) may be sited as a primary procedure [29]. For
some patients with communicating hydrocephalus it
may be possible to avoid cranial surgery by draining CSF
through serial lumbar puncture, a lumbar drain or a
lumboperitoneal shunt [29]. Endoscopic third ventricu-
lostomy may be used to treat some patients with non-
communicating hydrocephalus, but is skill and resource
intensive and may not be available in emergency or re-
source limited settings [14].
Why it was important to conduct this review
HIV-infected patients are at high risk of developing con-
ditions which predispose to hydrocephalus, such as
TBM or CM [36, 37]. However, VPS insertion which is a
mainstay of treatment for hydrocephalus in HIV non-
infected individuals might be particularly high risk in the
context of HIV: HIV infection might predispose to shunt
infection and patients with hydrocephalus in the context
of advanced HIV infection, might have such poor overall
predicted survival as to render neurosurgical interven-
tion futile or inappropriate [20, 38]. The literature from
HIV non-infected patient populations therefore cannot
be generalised to those with HIV infection. Clinicians
therefore require a dedicated synthesis of high-quality
evidence to appropriately counsel patients and their rela-
tives of the risks and benefits of VPS insertion in the
context of HIV.
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Aims and hypotheses
We aimed to identify all published studies of survival
and outcome in HIV-infected patients undergoing VPS
using a systematic review process and synthesise these
data using quantitative and narrative meta-analyses to
determine the risks and benefits of VPS insertion in the
context of HIV infection. We hypothesised that the
evidence base would be insufficient to reliably inform clin-
ical practice or to conduct quantitative meta-analysis.
Objectives
Our objectives were to: 1) Compare post-VPS mortality
at 12, 6 and 1months between the different aetiologies
of HIV-associated hydrocephalus; 2) Produce a narrative
review of risks of VPS infection and malfunction and
other complications in HIV-infected patients and; 3)
Identify baseline patient characteristics predictive of
good outcome following VPS in HIV infection.
Methods
Study design and protocol registration
We conducted a systematic review of all published lit-
erature stored in 10 electronic online databases, with no
language or date restrictions. Our study protocol has
been published in a peer-reviewed open access format
and is registered on PROSPERO (CRD42016052239) [39,
40]. The methods used are summarised here.
Eligibility criteria
To ensure that no relevant studies were arbitrarily ex-
cluded from this work, we included all studies which
met all of the below criteria:
Types of studies
Reports of randomised or non-randomised studies, ex-
cepting < 2-person case series, were eligible for
inclusion.
Types of participants
We included studies of HIV-infected patients aged 16
years or older who underwent a VPS procedure for any
indication. This included infectious and non-infectious
illness as well as illness unrelated to HIV status.
Types of interventions
We included studies which described VPS insertion
using any technique, catheter or valve.
Types of outcome measures
We included studied which reported overall survival,
AIDS specific mortality, VPS survival or measures of
functional outcome/disability. We defined VPS survival
as the proportion of patients who have a VPS which is
not causing symptoms and has not become infected or
undergone surgical revision or removal at any point.
Outcomes
Our primary outcome was one-year survival post-VPS in-
sertion with comparison between all identified aetiologies
of hydrocephalus. Secondary outcomes were overall sur-
vival, AIDS specific mortality, VPS survival, risk of peri-
operative complications and clinical outcome score [41–43]
at 1 month, 6 months and one-year post-VPS insertion.
Search methods for the identification of studies
Electronic searches
The following electronic online databases were systematic-
ally searched using terms for ventriculoperitoneal shunting
or CSF diversion and HIV infection (see supplementary
materials for full search strategies): The Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE
(PubMed), EMBASE, CINAHL Plus (EBSCOhost), LILACS
(BIREME), Research Registry (www.researchregistry.com),
the metaRegister of Controlled Trials (mRCT) (www.con-
trolled-trials.com), ClinicalTrials.gov (www.clinicaltrials.
gov) and African Journals Online (AJOL). Grey Literature
searching will be performed using the OpenGREY database.
These were last updated on 17 October 2019. Our search
sensitivity was validated confirming that candidate studies
identified during scoping searches are included in the
search yields [20, 44–46].
Searching other resources
The reference lists of included studies were scrutinized
to identify any additional studies for inclusion. Two ex-
perts in relevant fields (GM and GF) were consulted to
identify key studies not identified by electronic searches.
No hand searching was employed.
Data collection and analysis
Selection of studies
Each abstract was independently screened against eligi-
bility criteria by two of three reviewers (JL, NM, MP,
ST). Where eligibility criteria were met, or possibly met,
the full manuscript was obtained and reviewed by two
reviewers to determine final inclusion. Any disagree-
ments were resolved by consensus discussion.
Data extraction and management
Data was extracted using standardised proformas (supple-
mentary materials) and entered into Review Manager [47].
Reference management was done using EndNote [48].
Assessment of risk of bias in included studies
Each included study was initially assessed independently
for risk of bias by two reviewers (JL, MP, ST) using the
Canadian National Collaborating Centre for Methods
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and Tools domain based “Quality Assessment Tool for
Quantitative Studies” [49, 50]. Disagreement was re-
solved by consensus discussion.
Measures of effect
Our narrative review summarises each included study’s
reported measures of effect [39]. For quantitative meta-
analysis, we report pooled odds ratios [51].
Dealing with missing data
The corresponding authors of all published abstracts of
studies that were potentially eligible for inclusion, but
for which a full study report was not published, were
contacted electronically to request data not provided by
the abstract. All authors contacted were allowed a mini-
mum of 18 months to respond, prior to submission of
our completed article.
Assessment of heterogeneity
On the basis of extracted data, included studies were
compared for clinical and methodological heterogeneity.
Clinically and methodologically studies reporting similar
outcome measures at similar time points, were assessed
for statistical heterogeneity by calculation of the I2 statis-
tic (%) [47, 51]. We defined substantial heterogeneity as
I2 greater than 50%.
Data synthesis
Included studies were synthesised in a narrative review
addressing each of our pre-specified outcomes in turn.
The strength of the evidence available to inform each
outcome was assessed using the GRADE method and
summarised in summary of finding (SOF) tables using
GRADEpro [52]. Where substantial clinical, methodo-
logical or statistical heterogeneity was detected meta-
analysis was not attempted. Comparative meta-analysis
of homogenous studies was planned using the Peto
fixed-effects method [40]. However, as none of the stud-
ies were of high quality, study size varied, and as
between-studies variation in control matching was sig-
nificant, it was not clear that fixed-effect assumptions
were met. We therefore elected to use the Mantel-
Haenszel method, with random effects, and Review
Manager v5.3 [47]. As effect sizes from just two studies
could be determined it was not possible to generate
meaningful funnel plots. As criteria for further meta-
analysis were not met, only limited meta-analysis was
conducted. Our planned extended meta-analysis has
been detailed previously [39].
Availability of data
Lists of citations for each stage of review and risk of bias
assessment tables are available from the corresponding
author.
Results
Description of studies
Our literature search yielded 793 reports of studies, 721 of
which were unique. Two further reports were identified
by review of reference lists of included studies and were
considered for inclusion [53, 54]. yielding a total of 723
unique records for screening (Fig. 1). No further studies
were identified by expert opinion. 624 records were ex-
cluded by title and abstract screening. 33 records were se-
lected for full text review [8, 20, 44–46, 53–78]. Nine
studies met criteria for inclusion [44–46, 53, 72–75, 79]
and 24 were excluded [8, 20, 54–71, 80]. All included
studies were observational studies. Three studies included
a total of 75 patients with TBM [44, 46, 79] and six in-
cluded a total of 49 patients with CM [45, 53, 72–75].
Excluded studies
Of the excluded studies, 16 concerned CM [54–57, 59–
63, 66–69, 76, 78, 80], four TBM [20, 58, 64, 77], two
bacterial meningitis [70, 71], one coccoidal meningitis
[8], and one included only cases of diagnostic uncer-
tainty [65].
Two studies were published only in abstract form and
did not present sufficient outcome data for inclusion
[67, 68]. The corresponding authors of these records
were therefore contacted to request further details to as-
sess eligibility [8, 67, 68]. The authors one of these
responded but were unable to provide further informa-
tion [8, 68]. This study was therefore excluded.
The reasons for exclusion from this review are as fol-
lows: Two studies included patients with multiple, un-
documented modalities of CSF diversion [54, 55]; one
study provided a just single case report [56]; three stud-
ies reported just one or two cases of surgical interven-
tion and no survival/outcome data [57, 60, 61]; one
study included 44 patients who underwent VPS in the
context of CM but no outcome data [80]; two studies
were review articles [58, 66]; eight reported no HIV-
infected patients who underwent VPS [20, 59, 62–65, 71,
76–78]; in one study reporting < 50% HIV-infected pa-
tients it was not possible to associate outcome with HIV
status [8] and; no relevant measures of survival/outcome
were studied in four [67–70].
Studies of cryptococcal meningitis: characteristics and risk
of bias
As no comparative studies were included in this group it
was impossible to calculate size of effect. Characteristics
of included studies are summarised in Table 1 and risk
of bias in Table 2.
Bach, et al. 1997 [45]
This was a retrospective consecutive interrupted time
series of all patients admitted with severe intracranial
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hypertension (lumbar puncture opening pressure >
35cmCSF) secondary to CM who received CSF diver-
sion. Four patients received a VP shunt. Three patients
were initially managed with serial lumbar puncture. One
received primary VPS. All patients presented with visual
disturbance, one had seizures and one had bilateral ab-
ducens nerve palsies. Initial Glasgow Coma Score (GCS)
was not reported. Neither makes nor models of the VPS
systems used were described.
One patient was lost to follow-up at an unclear time
point. At 1 month, all three remaining patients were
alive. One death at 6 months was attributed to “wasting
syndrome”. At 10 months a further death was attributed
to Pneumocystis jiroveci pneumonia. Functional
Fig. 1 PRISMA Flow diagram of screened and included study reports
Table 1 Characteristics of included studies
Aetiology Number of patients
with HIV and VPS
Mean age
(years) (SD)a
Mean CD4 count
(cells/μL; ±SD)a
Included
outcome
Follow-
upb
Number of non-HIV infected
controls (mean age [±SD])
Country
Bach 1997 [45] CM 4 39.25 (±6.1) 28.75(±14.4) Survival 3d-12y N/A USA
Calvo 2003 [75] CM 5 28.2 (±7.7) unknown Survival 6 m N/A Uruguay
Cherian 2016 [74] CM 8 38.9 (±8.2) Unknown Survival 6 m-5.7y N/A USA
Corti 2014 [73] CM 14 33 (18–53)* 50 (6–511)* Survival 1y N/A Argentina
Liu 2014 [72] CM 9 32.2(±6.0) 10.75(±9.4) Survival 1 m-1y N/A China
Vidal 2012 [53] CM 9 Unknown Unknown Survival Discharge N/A Brazil
Nadvi 2000 [46] TBM 15 26.1 (±16.4) 171.7(±161.5) GOS 1m 15 patients (age 10.7[±9.6]) South
Africa
Sharma 2015 [44] TBM 30 31.3(±7.8) 143 (26–445)** GOS 3m 30 patients (age 31[±9.9]) India
Harrichandparsad
2019 [79]
TBM 30 28.4(±13.4) 227(±163.9) GOS 1m N/A South
Africa
*median (range); ** mean (range); a) HIV infected cohort, b) d = days, m =months, y = years
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outcomes, rates of shunt failure and complication were
not presented.
Although this study included consecutive patients and
therefore minimised selection bias, it was classified as
being globally weak. An interrupted time series is a weak
study design. Coupled with small sample size, this ren-
dered meaningful multivariable analysis impossible and
it was not attempted. The time until loss to follow up of
one patient was unclear, and the reasons for this are not
documented. Mortality is a robust outcome measure.
Calvo, et al. 2003 [75]
This is an interrupted time series that presents five HIV-
infected patients who were treated with VPS whilst ad-
mitted to a single Intensive Care Unit (ICU) in
Montevideo, Uruguay. It is unclear if the data was col-
lected in a prospective or retrospective fashion or
whether patients were recruited consecutively. Median
initial GCS was 12 (range 9–15). CD4+ cell count was
not reported for any patient, nor was the make or model
of VPS system. The VPS was inserted as a primary pro-
cedure for four patients with CSF pressures >23cmH2O.
One patient initially received an EVD with intraventricu-
lar pressure monitoring before having a VPS inserted.
All patients were managed with antifungal agents and
hyperventilation to a target pCO2 of 30 mmHg. Mannitol
boluses were used in an unclear number of patients. At
discharge from ICU all five patients were alive. Time to
discharge from ICU was not reported. At 6 months two
patients had been lost to follow-up and three survived.
Outcome in this study is described as “good recovery”,
“moderately disabled” or “dead” but the criteria for as-
signment to these descriptors are not described. At ICU
discharge, 4 patients had made a “good recovery” and
one was “moderately disabled”. At 3 months, two had a
“good recovery” and one was “moderately disabled”. No
complications or shunt failure are reported.
This study was classified as being globally weak with a
high risk of selection bias and weak study design which,
coupled with small sample size, did not permit adjust-
ment for modulators of risk of mortality or poor out-
come. Outcome assessment did not use a validated
outcome measure. 40% of patients were lost to follow-up
at 6 months.
Cherian, et al. 2016 [74]
This two-cohort analysis reported all patients with CM
and CM IRIS presenting to a single hospital in Texas,
USA. 49 of 50 patients had associated HIV infection.
Fourty patients had communicating hydrocephalus, and
it is unclear if the patient with non-communicating
hydrocephalus was HIV-infected or not. CD4+ cell
count was not documented for any patient, nor was ini-
tial neurological status. All further demographic and
outcome data are specific for the HIV-infected group.
Patients who went on to receive CSF diversion had ini-
tial lumbar puncture opening pressure > 25 cm H2O.
They were initially managed with antifungals, antiretro-
viral therapy and a variable number of therapeutic lum-
bar punctures (median 7; range 2–40) for a variable
period (median 27 days; range 4–281 days) before pro-
ceeding to VPS. Eight patients underwent VPS.
At 1 month, five of the eight VPS patients survived.
Three deaths had occurred, one due to post-extubation
aspiration pneumonia, one due to septic shock of un-
documented aetiology and the other due to a gram-
negative bacterial pneumonia. At 6 months, five patients
were still alive, and no new deaths were recorded. At 12
months, three patients were alive, four were dead and
one was lost to follow-up. The additional death was sec-
ondary to an unspecified respiratory complication. Of
the three patients initially treated for CM IRIS, at both
one and 6 months, two were alive and one dead. At 12
months, two were confirmed dead and the other lost to
follow-up.
One instance of shunt infection was recorded at 12
months. Two other patients, who were followed up for
1512 and 1485 days, suffered a shunt occlusion and a
shunt infection, respectively, at some point during their
follow-up period. However, the time to these complica-
tions was not reported. One other patient who was
followed up for 383 days suffered a subdural haematoma,
which was attributed to VPS over-drainage. Again, the
time point at which this occurred was not reported.
Functional outcomes were not reported.
Table 2 Quality assessment summary for cryptococcal meningitis studies
Using the Canadian national collaborating centre for methods and tools effective public health practice project Quality Assessment Tool for Quantitative
Studies [49]
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This study was classified as being globally weak with
no attempt to undertake multivariable survival analysis,
undocumented reasons for loss to follow-up and lack of
reporting of times of complications. Survival is a vali-
dated outcome measure but was unreliably reported in
patients discharged to hospice care. Rates of complica-
tion were not measured using a validated method. Pa-
tients were consecutively recruited, and the selection
process was clearly documented. A two-cohort analysis
study has moderate risk of bias.
Corti, et al. 2014 [73]
This retrospective interrupted time series included 15
patients with CM who presented to medical services in
Buenos Aires, Argentina. 14 of these patients were HIV-
infected, however it was not possible to identify which
demographic or outcome data pertained to the HIV-
non-infected patient. CSF diversion was undertaken in
patients who had lumbar puncture opening pressure
persistently > 25 cm H20 after 2 weeks of therapeutic
lumbar puncture and antifungal treatment. 14 of the 15
patients were managed with VP shunt, and one with
lumboperitoneal shunting. Again, it was not possible to
isolate demographic and outcome data from this patient.
Medtronic® systems were used for all patients but com-
ponent models are not described.
Three patients suffered complications including sepsis,
multiorgan failure, two cases of meningitis and abdom-
inal pseudocyst formation related to the distal catheter
tip and requiring catheter revision. These occurred at
unclear time points and the patients were excluded from
survival analysis by the study authors. However, the au-
thors did report that at least one of the patients with
meningitis and multiorgan failure died. Of the remaining
patients, all survived to 12 months. No other complica-
tions or outcomes were reported in this group.
This study was classified as being globally weak with
high risk of selection bias, a weak study design and small
sample size which did not permit adjustment for factors
potentially confounding outcome, and poorly docu-
mented exclusion from follow up causing high risk of at-
trition bias. Survival is a validated outcome measure but
was unreliably reported in the group with complications.
Liu, et al. 2014 [72]
This retrospective single cohort study included nine pa-
tients with HIV-associated CM managed with VPS over
a five-year period at a Shanghai hospital, China. Al-
though exclusion criteria are documented, the number
of exclusions is not. Included patients had a mean CD4+
cell count of 11 cells/μL. Neurosurgical intervention was
considered in patients with raised lumbar puncture
opening pressure and deteriorating neurological status
despite antifungal therapy, repeated therapeutic lumbar
puncture and mannitol administration. VPS was under-
taken in all patients using a Medtronic® system, but the
valve and catheter model are not documented. The au-
thors define raised opening pressure as “> 400 cm H20”
which, presumably, is a typographic error (raised CSF
opening pressure defined as > 20-35 cm H2O in other in-
cluded studies [45, 53, 73–75]). Two patients were de-
scribed as having loss of consciousness at baseline, but
no objective measures were provided.
Eight of the nine patients studied were alive at 1
month. Three patients were lost to follow up at 6
months and no new deaths were reported. At 12 months,
one more patient had died, yielding a survival of four
out of six patients for whom follow-up was available.
Given the low initial CD4 counts, it is likely that deaths
would have occurred in those lost to follow-up by this
time point and therefore there is a risk of attrition bias
at this time point. The causes of death were VPS ob-
struction at 1 month and an unspecified reaction to anti-
retroviral drugs at 12 months. No other outcome
measures, shunt failures or complications were reported.
This study was classified as being globally weak due to
a weak study design and unknown risk of selection bias.
No confounders were identified, and the primary out-
come was survival – which is a robust outcome
measure.
Vidal, et al. 2012 [53]
This retrospective cohort study investigated associations
between various parameters derived from quantitative
CSF microscopy with mortality in a cohort of patients
who presented to hospital in São Paulo, Brazil, with
HIV-associated CM. Included patients were admitted
between January 2006 and June 2008, but it is unclear
what rate of case acquisition this represents. A median
CD4+ cell count of 36 cells/μL, with interquartile range
of 17–87 cells/μL was reported across all patients.
Neurosurgical intervention was considered in patients
with lumbar puncture opening pressure persistently
>20cmH2O after 14 days therapeutic lumbar puncture
and antifungal treatment.
Although survival was presented in the series of 9 pa-
tients undergoing VPS, no other dependent or independ-
ent variables were reported in this subgroup to allow
comparisons and therefore, for our purposes, this study
provided case-series data. Initial neurological status and
type of shunt valve or catheter were not described. Of
the 9 patients who underwent VPS, 6 survived until hos-
pital discharge. However, time to discharge and length
of stay were not reported. No other outcomes were
reported.
This study was classified as being globally weak with
an unknown risk of selection bias and weak study design
and size which did not permit adjustment for
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confounding variables regards our research question.
Survival is a strong primary outcome measure.
Included studies of tuberculous meningitis: characteristics
and risk of bias
Nadvi, et al. 2000 [46]
This prospective cohort analysis compared outcome and
mortality at 1 month following VPS between HIV-
infected and HIV non-infected patients. Patients who
underwent VPS for TBM, over an undefined recruitment
period prior to commencement of the national South
African antiretroviral treatment (ART) programme in
2004, were recruited from a single hospital in KwaZulu-
Natal, South Africa. Of the 30 patients recruited, 15
were HIV-infected and 15 HIV non-infected. The two
cohorts differed widely in age range with the HIV-
infected group being mostly adult and the HIV non-
infected group being mostly paediatric. Patients were di-
agnosed with hydrocephalus on the basis of CT, trans-
cranial doppler or clinical observation in keeping with
hydrocephalus and intraoperative ventricular pressure >
20cmCSF. Median initial GCS was 14 (range 9–15) in
the HIV-infected group and 12 (range 9–15) in the HIV
non-infected group. Use of EVD or therapeutic lumbar
puncture was not documented for any patient. VPS was
undertaken using a 102 cm catheter and low-profile,
medium pressure Codman / Unishunt valve (Codman /
Johnson & Johnson®, Raynham, MA).
At 1 month, 5/15 and 11/15 HIV-infected, and HIV
non-infected patients were alive, respectively. 11/15 and
6/15 patients in the HIV-infected and HIV non-infected
cohorts had an unfavourable Glasgow Outcome Score
[43] (GOS 1–3) dichotomised GOS at 1 month. Multi-
variable analysis was not attempted. Univariate analysis
revealed a significant association of CD4+ cell count and
outcome (p = 0.031), but the magnitude of this associ-
ation was not reported.
This study was classified as being globally weak. A
prospective cohort study provides a moderate study de-
sign. The study included representative patients, but the
control group was poorly age matched and this was not
adjusted for. It is not clear that patients were enrolled
consecutively, yielding an unknown risk of selection bias.
The authors were not blinded to HIV status. Mortality is
a robust primary outcome measure. As this study was
undertaken prior to ART being made widely available in
South Africa, its findings may not be generalisable to
settings where ART is available [81].
Sharma, et al. 2015 [44]
This retrospective case-control study compared outcome
and mortality between HIV-infected and HIV non-
infected patients following VPS. All 30 eligible HIV-
infected patients who underwent VPS at a single hospital
in Bangalore, India, between June 2002 and October
2012 were included. These patients were compared
against 30 HIV non-infected control patients that were
matched for age, sex and clinical grade of TBM. Patients
were included who “had symptoms of raised intracranial
pressure, with clinical, radiological and CSF findings
characteristic of TBM”. However, specific inclusion cri-
teria were not documented. Initial GCS was dichoto-
mized as 3–8 (unfavourable) and this was present in
13.3 and 3.3% in the HIV-infected and non-infected pa-
tients, respectively. The rest had GCS 9–15, which was
classified as favourable. 23 and 22 patients in the HIV-
infected and non-infected cohorts, respectively, had
communicating hydrocephalus. Patients underwent VPS
as a primary procedure unless extensive basal infarcts
were evident on computed tomography (CT) scan of the
brain. In these patients, a frontal EVD was placed and
converted to VPS if improvement in “sensorium” was
noted. The proportion of those who underwent primary
VPS is not reported. VPS was with a medium-pressure
Chhabra shunt (Surgiwear® Inc.). 9 HIV-infected patients
and 4 HIV non-infected patients were lost to follow-up.
At 1 month, 13/21 HIV-infected and 20/26 HIV non-
infected patients were alive. At 6 months, 9 HIV-
infected and 18 HIV non-infected patients were alive. In
the HIV-infected cohort, unfavourable initial GCS was
associated with higher rates of mortality. GOS at 3
months was also dichotomized as unfavourable (1–3) or
favourable (4, 5). 16/21 HIV-infected, and 9/26 HIV-
non-infected patients had an unfavourable outcome at 3
months. Binomial logistic regression analysis confirmed
that HIV infection (p = 0.038) and low Palur grade (p =
0.024) [82] were significantly associated with unfavour-
able outcome. No measure of effect was presented for
these analyses. Anaemia (haemoglobin < 10 mg/dL) was
associated with unfavourable outcome in the HIV-
infected group (Exp.[β] = 25.6; p = 0.011).
This study was classified as being globally of moderate
quality. A case-control study provides a moderate quality
of study design. The study included representative con-
secutive cases with appropriate matching of controls. Po-
tential confounders were adjusted for in the
multivariable analysis. The authors were not blinded to
HIV status. Just under a third of initially recruited pa-
tients were lost to follow-up at later time points, but this
was appropriately documented. GCS and dichotomised
GOS are robust outcome measures but not validated in
the context of TBM. Mortality is a robust outcome
measure.
Harrichandparsad, et al. 2019 [79]
This case control study compared 15 HIV-infected pa-
tients who were using ART prior to presentation who
consecutively underwent VPS for TBM in 2017 with 15
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historical retrospectively identified controls who under-
went the same procedure but were not using ART. All
patients receiving ART were prescribed single pill for-
mulation of tenofovir and emtricitabine as well as efavir-
enz. The diagnosis of TBM was made on the basis of
typical clinical, radiological and CSF findings. Not all pa-
tients had positive CSF cultures. All patients had radio-
logical features of hydrocephalus with CSF pressures
higher than 20 cm H2O on ventriculostomy and under-
went VPS as a primary procedure. Both cohorts had
similar initial GCS and Palur grade on admission.
All patients were followed up as inpatient for a
minimum of 1 month post-operatively. Outcome was
assessed at discharge using the dichotomised GOS (GOS
4–5 good outcome; 1–3 poor outcome). At discharge
overall 15 patients achieved good outcome, one poor
outcome and four died. Eleven patients receiving anti-
retroviral therapy achieved a good outcome with no in-
stances of poor outcome and four deaths. This was
better than the historical control group only four of
which achieved a good outcome, one poor outcome and
ten deaths. This difference was statistically significant in
unadjusted analysis (p = 0.027). Patients in the ART
treated group were more likely to have a higher GCS at
1 month than at presentation than the ART untreated
group (p = 0.042).
This study was classified as being globally weak. A
case-control study provides a moderate quality of study
design. Consecutive patients were enrolled, reducing
chances of selection bias and there was no attrition. Al-
though matching of cases and controls by severity was
attempted, differences in spread of age and gender were
present. These were not statistically significantly differ-
ent between groups at p < 0.05, but this may reflect high
variation in these characteristics and the multivariable
analysis that would be required to adjust for these was
not possible. The study describes no blinding. GCS and
dichotomised GOS are robust measures but not vali-
dated in the context of TBM. Mortality is a robust out-
come measure.
Risk of bias between studies: tuberculous meningitis
As two comparative cohort studies were included asses-
sing the effect of HIV infection on outcome, it was pos-
sible to pool reported measures of effect of HIV-
infection on survival at one-month post-VPS. Risk of
bias is summarised in Table 3.
Synthesis of results
Effect of pathology
Nine studies of survival and/or outcome in TBM and
CM were identified [44–46, 53, 72–75, 79]. However,
none of these compared survival or outcome between
TBM and CM. Study populations, outcome measures
and follow-up varied greatly. Further, all of the studies
of CM were of weak design, and two of the three studies
of TBM also being graded as weak. There was significant
methodological heterogeneity between CM and TBM
studies and it was therefore not possible to conduct
meaningful meta-analytic comparison of outcomes be-
tween these groups. We therefore present a narrative
analysis. The results of pooling of reported outcomes
within each group are presented in SOF tables, with the
purpose of summarising reported outcomes to date.
These are of very low to low GRADE of evidence (see
risk of bias, above), indicating that the true outcomes for
each pathology may be, or are likely to be, substantially
different from the pooled measure [83]..
Cryptococcal meningitis
Pooled outcome measures are reported in Table 4.
Survival
Three studies reported survival in CM at one-month
post VPS [45, 72, 74]. Cherian, et al. reported three
deaths in eight patients. Three of these patients had a
diagnosis of CM IRIS, one of which died (AIDS-specific
mortality). Liu, et al. report one death in nine patients at
1 month. This was due to shunt obstruction. Bach,
et al.’s four patients with documented follow up were all
alive at 1 month. In total, 17 of 21 (81%) patients de-
scribed in these studies survived 1 month, with one epi-
sode of shunt failure documented.
At 6 months post-VPS, four studies reported survival
[45, 72, 74, 75]. Three of Liu, et al’s patients had been
lost to follow-up. However, no new deaths were con-
firmed. Bach, et al. reported one death due to HIV-
wasting syndrome. Another had died of cytomegalovirus
pancreatitis. These both therefore contributed to AIDS-
specific mortality [84]. Calvo, et al. obtained 3 months
follow up for three patients, all of whom survived. Cher-
ian et al. followed up all of their eight patients and re-
ported no new deaths. With loss to follow-up and
addition of three surviving patients from Calvo, et al’s
cohort, overall survival remained stable: 17 of 21 (81%)
patients that were followed up at 6 months were alive.
No new cases of shunt failure were documented.
Four studies reported 12-month survival [45, 72–74].
Liu, et al. reported a further death. Cherian, et al. re-
ported a death in one of their patients who had been di-
agnosed with CM IRIS, contributing to AIDS-specific
mortality. Another of their patients was lost to follow-
up. One of Bach et al.’s patients had died of Pneumocyc-
stis jiroveci pneumonia, also contributing to AIDS-
specific mortality. Corti, et al. report that all of their 12
patients followed-up for 1 year were alive. In total 20 of
29 patients with 12-month follow-up survived. Five of
the 17 (29%) patients reported by studies describing
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Table 3 Quality assessment summary for tuberculous meningitis studies
Using the Canadian national collaborating center for methods and tools effective public health practice project Quality Assessment Tool for Quantitative
Studies [49]
Table 4 Summary of findings – cryptococcal meningitis
Outcomes Pooled
outcome
№ of participants
(studies)
Quality of the
evidence (GRADE)
Comments
Survival
Survival follow up: 1
months
17 (81.0%; range
62.5–100%)
21 (3 observational
studies) [45, 72, 74]
⨁◯◯◯
VERY LOW a,b,d,f,g,h,k
Survival follow up: 6
months
16 (76.2%; range
62.5–100%)
21 (4 observational
studies) [45, 72, 74, 75]
⨁◯◯◯
VERY LOW a,b,d,f,g,h
Survival follow up: 12
months
20 (69.0%; range
33–100%)
29 (4 observational
studies) [45, 72–74]
⨁◯◯◯
VERY LOW a,b,d,f,g,h,i
AIDS specific mortality
AIDS specific mortality
follow up: 1 months
1 (4.8%; range
0–12.5%)
21 (3 observational
studies) [45, 72, 74]
⨁◯◯◯
VERY LOW a,b,d,f,g,h,k
AIDS specific mortality
follow up: 6 months
3 (16.7%; range
12.5–33%)
18 (3 observational
studies) [45, 72, 74]
⨁◯◯◯
VERY LOW a,b,d,f,g,h,k
AIDS specific mortality
follow up: 12 months
5 (29.4%; range
25–66%)
17 (3 observational
studies) [45, 72, 74]
⨁◯◯◯
VERY LOW a,b,d,f,g,h,k
VPS survival
VPS survival follow up:
1 months
8 (88.9%) 9 (1 observational study)
[72]
⨁◯◯◯
VERY LOW a,d,e,f,g
Cherian, et al. [74] reported two shunt failures at
unspecified timepoints.
Corti, et al. [73] reported three shunt failures at
unspecified timepoints.
VPS survival follow up:
6 months
5 (83.3%) 6 (1 observational study)
[72]
⨁◯◯◯
VERY LOW a,d,e,f,g
Cherian, et al. [74] reported two shunt failures at
unspecified timepoints.
Corti, et al. [73] reported three shunt failures at
unspecified timepoints.
VPS survival follow up:
12 months
5 (83.3%) 6 (1 observational study)
[72]
⨁◯◯◯
VERY LOW a,d,e,f,g
Cherian, et al. [74] reported two shunt failures at
unspecified timepoints and one at 12months.
Corti, et al. [73] reported three shunt failures at
unspecified timepoints.
Operative complication 4 (23.5%; range
0–50%
17 (2 observational
studies) [72, 74]
⨁◯◯◯
VERY LOW
a,b,c,d,e,f,g
Corti,et al. [73] reported one case of multiorgan failure
or unspecified aetiology.
Validated outcome score No studies reported validated outcome measures at any time
point
Calvo, et al. [75] reported unvalidated outcome
measures at 6 months
a. Possibly selected observational case series
b. Population includes some HIV non-infected individuals
c. Outcomes reported at different time points for different patients
d. Population derived from a study indirectly addressing question
e. Outcomes not fully defined
f. CD4 count not described or unusually low in some studies
g. Population baseline characteristics described incompletely
h. Significant loss to follow up
i. Exclusion of patients who suffered postoperative complications
k. Loss of case to follow up at unspecified time point
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cause of death had AIDS-defining illness as a primary or
major contributing cause of death by 12months.
Liu et al., reported one shunt failure at 1 month. Cher-
ian and colleagues reported one shunt failure at 12
months, but as they also reported two other instances of
shunt failure at unclear timepoints, their shunt failure
data was not included in the pooled analysis.
Operative complications
Complications of treatment were reported by two
studies [72, 74]. In Liu, et al.’s series, none of these
were related to the surgical management of their pa-
tients at 12 months. In addition to their three in-
stances of shunt failure, Cherian and colleagues
reported one instance of over drainage subdural
haematoma at an unspecified time. Follow-up in this
series ranged from 28 to 1512 days.
Functional outcome
No studies reported any measures of functional outcome
at any time point. Calvo, et al. reported that two of three
patients made a “good recovery” at 6 months but this
measure is not validated [75].
Tuberculous meningitis
Pooled outcome measures are reported in Table 5.
Survival
Three studies reported 1-month survival following VPS
for HIV-associated TBM [44, 46, 79]. Sharma et al. re-
ported 13 of 21 patients surviving for one-month post-
VPS. Nadvi, et al. reported just 5 of 15 patients surviving
for one-month. Harrichandparsad, et al. reported 14 out
of 30 patients surviving for 1 month, although 10 of
these deaths were in the ART untreated group.
Sharma et al. reported 9 of 21 patients surviving 6
months. Sharma et al. also reported “long-term” survival
of 7 of 21 with mean follow-up of 130 days, range 91–
760 days. No studies reported causes of death or mea-
sures of shunt survival.
Operative complications
No studies reported rates of operative complication.
Functional outcome
Two studies reported GOS in HIV-infected patients 1
month following VPS [46, 79]. 11 of 15 patients in
Nadvi, et al.’s study had an unfavourable functional out-
come, with 10 of these being dead. Therefore four of the
five surviving patients attained GOS 4–5, signifying
moderate to low levels of disability at one month [43].
Harrichandparsad, et al. reported 15 of 30 patients
achieving an unfavourable outcome, including death at
Table 5 Summary of findings – tuberculous meningitis
Outcomes Pooled outcome № of participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Survival
Survival follow up: 1
months
34 (51.5%; range 33.3–
61.9%)
66 (3 observational studies) [44,
46, 79]
⨁⨁◯◯
LOW a
Survival follow up: 6
months
9 (42.9%) 21 (1 observational study) [44] ⨁◯◯◯
VERY LOW a,b
Survival follow up: 12
months
7 (33.3%) 21 (1 observational study) [44] ⨁◯◯◯
VERY LOW a,b
AIDS specific mortality No studies reported AIDS specific mortality at any point
VPS survival No studies reported VPS failure or survival rates at any time point
Operative complication No studies reported rates of operative complication at any time point
Validated outcome score
Glasgow outcome score
(GOS)
follow up: 1 month
GOS 1–3: 26 (57.8%)
GOS 4–5: 19 (42.2%)
45 (2 observational studies)
[46, 79]
⨁⨁◯◯
LOW a
GOS 1–3 signifies death to severe
disability
GOS 4–5 signifies moderate to low
disability
Glasgow outcome score
(GOS)
follow up: 6 months
GOS 1–3: 16 (76.2%)
GOS 4–5: 5 (23.8%)
21 (1 observational study) [46] ⨁◯◯◯
VERY LOW a,c
GOS 1–3 signifies death to severe
disability
GOS 4–5 signifies moderate to low
disability
Glasgow outcome score
(GOS)
follow up: 12 months
No studies reported a validated outcome score at 12 months
a Possibly selected observational case series level data
b Incomplete long-term follow-up
c Mean follow up 130 days. Range of 3–25 months
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one month, 11 of which were in the ART untreated
group [79].
Effect of human immunodeficiency virus infection
As two studies comparing HIV-infected and HIV non-
infected patients with TBM were identified, it was pos-
sible to examine the impact of HIV-infection on survival
[44, 46].
At 1 month, the odds ratio for mortality in Sharma,
et al.’s HIV-infected group was 2.02 (95% confidence
interval [CI]: 0.58–7.01). In Nadvi’s group it was 4.73
(95% CI: 0.58–7.01). The pooled odds ratio (Mantel-
Haenszel) for one-month mortality in the HIV-infected
group was 3.03 (95% CI: 1.13–8.12; p = 0.03; chi2 = 0.92;
df = 2; I2 = 0%; Fig. 2), indicating significantly increased
risk of mortality at one-month post-VPS in HIV
infection.
Sharma et al. reported six-month survival, but Nadvi,
et al. did not.
Discussion
Summary of evidence
Only studies of patients with who underwent ventriculo-
peritoneal shunting because of HIV-associated hydro-
cephalus secondary to TBM or CM were identified by
our study. Six series of patients with CM [45, 53, 72–75]
and two controlled studies of patients with TBM [44,
46] were included.
Cryptococcal meningitis
The included studies of CM provided a very low level of
evidence on which to inform clinical practice. Reported sur-
vival by included studies of CM varied extremely widely –
from 33 to 100% at 1 year – and this is likely a consequence
of study heterogeneity. The relatively high pooled 12-
month survival of 69% might represent selection and attri-
tion biases, which many included studies were considered
to be at a high risk of. For comparison, 12-month survival
in a study of 549 patients with HIV-associated CM who did
not receive shunting varies from 55 to 93%, contingent on
patients’ antiretroviral status [85].
The 2018 World Health Organisation (WHO) guide-
lines on CM recommend that CM-associated hydro-
cephalus be initially managed by therapeutic lumbar
puncture and drainage of CSF [86]. These guidelines
emphasise that repeat lumbar puncture should be under-
taken to control symptomatic hydrocephalus until reso-
lution and do not describe any role for permanent CSF
diversion in CM. The Infectious Diseases Society of
America 2010 guidelines for the management of crypto-
coccal disease recommended early ventricular CSF diver-
sion for non-communicating hydrocephalus in CM [87].
For chronic communicating hydrocephalus or communi-
cating hydrocephalus causing significant neurological
impairment, permanent CSF diversion may be under-
taken [87].
Tuberculous meningitis
Three cohort studies were included. These provide a low
level of evidence to inform prognostication at one-
month, in terms of survival and functional outcome, for
patients undergoing VPS for HIV-associated TBM. One-
month survival varied from 33 to 61.9% between these
studies, yielding a very cautious pooled estimate of one-
month survival of 51.5% and a pooled estimate of 42.2%
good outcome at 1 month. We anticipate that this esti-
mate differs substantially from the true outcome. The in-
cluded studies provide a very low level of evidence to
inform later prognostication in terms of survival and
functional outcome. For all other measures of outcome
– including AIDS-specific mortality, shunt failure risk
and perioperative complication – the included studies
provided no data to inform clinical decision-making.
Nadvi, et al. and Sharma, et al’s studies demonstrate that
patients who underwent VPS for HIV-associated TBM
had poorer outcomes than their HIV non-infected coun-
terparts. Meta-analysis of these findings yielded in-
creased risk of mortality (odds ratio 2.93) in the HIV-
infected group. However, one of these studies compared
a largely paediatric HIV non-infected population with a
largely adult HIV-infected population [46]. The clinical
phenotypes and pathophysiological responses to brain
injury in these groups differ widely and so comparisons
should be interpreted with caution [88, 89]. It is also im-
portant to note that whilst one of the studies employed
ventricular CSF diversion as a primary measure for man-
agement of hydrocephalus [44], it is unclear if this was
undertaken primarily, or following failure of lumbar
Fig. 2 Forest Plot - One-month mortality HIV-infected vs. HIV non-infected tuberculous meningitis
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drainage/medical management in the other study [46].
This heterogeneity limits the interpretation of compari-
sons between reported outcomes in HIV-infected and
non-infected cohorts.
The British Infection Society published guidelines in
2009 for the management of TBM [90]. These guidelines
did not recommend altering the medical management of
patients with TBM on the basis of their HIV status but
did not comment on their surgical management with re-
spect to HIV. On the basis of observational studies of
HIV non-infected patients, early VPS is recommended
by these guidelines for non-communicating hydroceph-
alus [90–92]. It is noted that response to external ven-
tricular drainage poorly predicts response to VPS [91].
Our study’s findings would indicate that HIV status
might impact significantly on surgical outcome and
therefore caution should be employed by future guide-
line working groups before generalizing the results of
studies conducted of HIV non-infected populations to
inform the surgical management of HIV-infected
patients.
Review limitations
This review is limited in certain respects. As just two
studies reporting effect sizes could be included in our
meta-analysis, it was not possible to meaningfully assess
for publication bias. Publication bias in case series tends
to over-represent good outcomes and therefore our
pooled results are likely to indicate better survival and
outcomes than is the truly the case [93]. Included stud-
ies in our review were of low-moderate quality study de-
sign. The decision to utilise designs such as single
cohort studes or small case series is often a pragmatic
choice on behalf of the study authors: conduct of larger
standardised observational studies, with blinding of out-
come assessment and multivariable adjustment of factors
influencing clinical outcome may not have been justified
by available resources. Unfortunately, observer bias and
the effect of unmeasured confounding factors in these
types of study can substantially impact on study out-
come and this therefore reduces our confidence in our
pooled estimates of outcome following VPS insertion in
HIV-infected individuals [94, 95].
Four of our included studies were published 1997–
2003, prior to the widespread availability of ART [81].
Use of ART is an important predictor of survival and
this could potentially impact on the generalisability of
these studies outcomes to contemporary practice [86,
90]. These included Nadvi et al’s study of TBM, which
reported lower one-month survival (at 33%) than the
more recent study by Sharma, et al. (61.9%) [44, 46, 81].
Harrichandparsad, et al. directly assessed the impact of
ART provision and showed a dramatic, yet expected, as-
sociation between ART provision and better outcomes
in the context of TBM (ART 73% vs. no ART 33% 1
month survival) [79]. It is striking that 1 month survival
in this small ART treated cohort is similar to that of the
pooled data from HIV uninfected patients in Sharma
et al., and Nadvi, et al’s studies (75.6%). Two studies of
CM published in 2003 [75] and 1997 [45] reported 0–
50% 6month mortality, respectively. However, these
contributed small numbers of cases to our analysis of
CM and so the effect of lack of availability of ART for
these cases on our analysis is likely less than the effect of
other factors such as incomplete follow-up.
Suggestions for future research
Our review has included studies of patients with either
TBM or CM. Although other causes of hydrocephalus in
HIV have been reported, none of these reports met our
criteria for inclusion [5–8, 96, 97]. Understanding how
outcomes differ following VPS insertion in HIV-infected
and non-infected patients with causes of hydrocephalus
not directly attributable to HIV infection (e.g. subarach-
noid haemorrhage, Chiari malformation, etc) would
allow determination of the relative impacts of undertak-
ing VPS in the context of active CSF infection and HIV-
infection. Unfortunately, to date, most large studies of
VPS insertion for “all cause” hydrocephalus have ex-
cluded HIV-infected patients, have been conducted in
populations with low HIV-infection prevalence, or do
not report HIV-infection rates within their cohort [30,
98, 99].
Furthermore, our review has provided evidence that
available data is of inadequate quality to reliably inform
clinical decision-making related to VPS insertion for
HIV-associated CM and TBM. The burden of HIV-
associated CM and TBM in low-middle income settings
in the era of ART are unclear yet believed to remain sig-
nificant, with one study estimating over 600,000 HIV-
associated CM deaths occurring in 2006 [37] and TBM
and CM accounting for approximately 10% of AIDS re-
lated deaths in a Ghanaian study from 2007 [36]. As
hydrocephalus or raised CSF pressure is present in ap-
proximately 50% of cases of HIV-associated TBM [100,
101] and 60% of HIV-associated CM [102], the lack of
evidence to guide use of VPS in this setting is
concerning.
We therefore propose that a large, multi-centre, pro-
spective, population-based survival analysis of all pa-
tients with HIV-infection and hydrocephalus be urgently
conducted. This should include both surgically and non-
surgically managed patients with hydrocephalus occur-
ring in association of HIV, either as a consequence of
HIV-infection or any other cause, not directly related to
HIV-infection. Such a study should collect baseline clin-
ical data – such as pre-admission ART use, neurological
grade, CD4+ cell count, haemoglobin and CSF cell
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count, protein and glucose, microbiological results and
opening pressure – which are currently used to prognos-
ticate and guide selection of surgical candidates. Ideally,
all included patients would be matched to HIV non-
infected controls, however identification of appropriate
control subjects might be difficult for conditions such as
CM, which infrequently affect HIV non-infected individ-
uals [103]. This study would allow validation of these
potential markers of prognosis and would allow identifi-
cation of patient groups for which there may be equi-
poise regarding the benefit and harms of VPS. Definition
of such populations would provide a strong rationale for
undertaking an appropriately powered randomised clin-
ical trial, conducted in low-middle income settings.
Conclusions
It is not possible to reliably determine the risks and bene-
fits of VPS surgery in patients with HIV on the basis of
the currently available literature. All studies of outcomes
following VPS for HIV-associated CM are weak, with only
case-series data available. Studies of survival and/or out-
come following VPS for HIV-associated CM and TBM are
either weak or of moderate quality. This included three
cohort studies of patients with TBM, at differing risk of
bias. Included studies indicate that only a very low to low
quality evidence base exists on which to inform clinical
decision making regarding VPS insertion for HIV-infected
patients. This is reflected in weak recommendations in
existing clinical guidelines for neurosurgical practice in
HIV-infected patients [87, 90, 104, 105]. In the first in-
stance, a rigorously conducted prospective, population
based observational study of outcome and survival in
HIV-associated hydrocephalus should be conducted. This
is an urgent research priority and would inform design of
future randomised clinical trials.
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